Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time REDWOOD CITY, Calif., Oct.

RASMULTI（ON）抑制剂RMC-6236的临床剂量递增数据显示口服生物利用度，良好耐受的安全性和跨多个RAS突变的抗肿瘤活性的初步证据首次临床数据介绍RMC-6291，一种RASG12C（ON）抑制剂，突出了令人鼓舞的初始耐受性，安全与差异化抗肿瘤活动投资者网络广播将于10月22日星期日晚上12:30在加利福尼亚州红木城举行。

13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies.

132023（GLOBE NEWSWIRE）-Revolution Medicines，Inc。（纳斯达克股票代码：RVMD）是一家为RAS成瘾癌症开发靶向治疗的临床阶段肿瘤公司，今天宣布鼓励RMC-6236，其RASMULTI的初步临床数据（ON）抑制剂和RMC-6291，其RASG12C（ON）抑制剂，来自各自的1/1b期研究。

These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) in Boston, October 11-15, 2023. “We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly.

这些数据于2023年10月11日至15日在波士顿举行的2023年AACR-NCI-EORTC分子靶点和癌症治疗国际会议（“三次会议”）期间提交。“我们很高兴报告RMC-6236和RMC-6291这两种开创性的RAS（ON）抑制剂的令人鼓舞的临床数据，这些抑制剂广泛地为我们的RAS（ON）抑制剂平台提供了强有力的验证。

The RMC-6236 safety data support that this highly innovative, oral RASMULTI Inhibitor is generally well tolerated across dose levels in patients, exhibits dose-dependent pharmacokinetics reaching exposures predicted preclinically to induce tumor regressions and induces molecular responses (ctDNA) and radiographic regressions suggestive of anti-tumor activity targeting multiple common RAS mutants that cause cancer, including KRASG12D and KRASG12V,” said Mark A.

RMC-6236安全性数据支持这种高度创新的口服RASMULTI抑制剂在患者的剂量水平上通常具有良好的耐受性，展示剂量依赖性药代动力学，达到临床前预测的暴露诱导肿瘤消退并诱导分子反应（ctDNA）和放射照相回归，提示针对导致癌症的多种常见RAS突变体（包括KRASG12D和KRASG12V）的抗肿瘤活性，“Mark A。

Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “The RMC-6291 data provide important initial evidence that this m.

Goldsmith，M.D.，Ph.D.，首席执行官和革命药物主席。“RMC-6291数据为这一m提供了重要的初步证据。